Research programme: cancer therapeutics - Therapure Biopharma/BioVectra
Latest Information Update: 16 Jun 2014
At a glance
- Originator BioVectra; Therapure Biopharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Jun 2014 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 18 Jan 2013 BioVectra has been acquired by Questcor Pharmaceuticals
- 06 May 2011 No development reported - Preclinical for Cancer in Canada (unspecified route)